Year-end Sale % OFF 
Abstract
PurposeCollagen peptides (CPs) and calcium citrate are commonly used as bone health supplements for treating osteoporosis. However, it remains unknown whether the combination of oral bovine CPs with calcium citrate is more effective than administration of either agent alone.MethodsForty 12-week-old Sprague-Dawley rats were randomly divided into five groups (n = 8) for once-daily intragastric administration of different treatments for 3 months at 3 months after ovariectomy (OVX) as follows: sham + vehicle; OVX + vehicle; OVX + 750 mg/kg CP; OVX + CP-calcium citrate (75 mg/kg); OVX + calcium citrate (75 mg/kg). After euthanasia, the femurs were removed and analyzed by dual energy X-ray absorptiometry and micro-computed tomography, and serum samples were analyzed for bone metabolic markers.ResultsOVX rats supplemented with CPs or CP-calcium citrate showed osteoprotective effects, with reductions in the OVX-induced decreases in their femoral bone mineral density. Moreover, CP-calcium citrate prevented trabecular bone loss, improved the microarchitecture of the distal femur, and significantly inhibited bone loss with increased bone volume, connectivity density, and trabecular number compared with OVX control rats. CP or CP-calcium citrate administration significantly increased serum procollagen type I N-terminal propeptide levels and reduced serum bone-specific alkaline phosphatase, osteocalcin, and C-telopeptide of type I collagen levels.ConclusionsOur data indicate that combined oral administration of bovine CPs with calcium citrate inhibits bone loss in OVX rats. The present findings suggest that combined oral administration of bovine CPs with calcium citrate is a promising alternative for reducing bone loss in osteopenic postmenopausal women.
Highlights
Osteoporosis is the general skeletal disease that features in osteopenia
OVX rats supplemented with Collagen peptides (CPs) or CP-calcium citrate showed osteoprotective effects, with reductions in the OVX-induced decreases in their femoral bone mineral density
CP-calcium citrate prevented trabecular bone loss, improved the microarchitecture of the distal femur, and significantly inhibited bone loss with increased bone volume, connectivity density, and trabecular number compared with OVX control rats
Summary
Osteoporosis is the general skeletal disease that features in osteopenia. It involves degradation of the skeletal microstructure, and may cause increases in skeletal osteopsathyrosis and bone fractures. Treatments for osteoporosis are associated with huge expense, which conveys a burden on either society or the patient’s family. Osteoporotic patients and their families suffer from pain physically and spiritually. The effective therapeutic drugs for osteoporosis include antiresorptive drugs, such as diphosphonates, selective estrogen receptor modulators (SERMs), and receptor activator of NF-kappa-B ligand (RANKL) inhibitors [3], and drugs for improving constructive metabolism, such as parathyroid hormone [4]. Owing to the side effects of the abovementioned drugs and the limitations of single drugs for therapeutic effects on osteoporosis, extensive research is expected to be conducted to seek new drug targets and achieve the purposes of elevating bone mineral density (BMD), improving bone structure, and increasing bone strength [8,9]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
